ArticlePloS one2014
Proteomics-identified Bvg-activated autotransporters protect against bordetella pertussis in a mouse model.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection Model.medRxiv : the preprint server for health sciences · 2026Article
- Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.NPJ vaccines · 2024Review
- Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice.NPJ vaccines · 2024Article
- Review
- Article
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.Frontiers in immunology · 2021Article
- Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract.Vaccines · 2020Review
- Complement Evasion Strategies of Human Pathogenic Bacteria.Indian journal of microbiology · 2020Review
- Identification of the minimum region of Bordetella pertussis Vag8 required for interaction with C1 inhibitor.Microbiology and immunology · 2020Article
- The Role of Virulence Proteins in Protection Conferred byVaccines · 2020Article
- Acellular Pertussis Vaccines Induce Anti-pertactin Bactericidal Antibodies Which Drives the Emergence of Pertactin-Negative Strains.Frontiers in microbiology · 2020Article
- Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site.PloS one · 2020Article
- Catch Me if You Can: Streptococcus pyogenes Complement Evasion Strategies.Journal of innate immunity · 2019Review
- Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.Infection and immunity · 2018Article
- Bordetella pertussis isolates vary in their interactions with human complement components.Emerging microbes & infections · 2018Article
- Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.Medical microbiology and immunology · 2018Review
- Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing toMolecular & cellular proteomics : MCP · 2018Article
- Virulence Associated Gene 8 ofFrontiers in immunology · 2018Article
- Comparison of the Whole Cell Proteome and Secretome of EpidemicFrontiers in microbiology · 2018Article
Corrections and comments
- Erratum issuedGouw, Daan de [corrected to de Gouw, Daan; Jonge, Marien I de [corrected to de Jonge, Marien I]
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis is a highly infectious respiratory disease of humans caused by the bacterium Bordetella pertussis. Despite high vaccination coverage, pertussis has re-emerged globally. Causes for the re-emergence of pertussis include limited duration of protection conferred by acellular pertussis vaccines (aP) and pathogen adaptation. Pathogen adaptations involve antigenic divergence with vaccine strains, the emergence of strains which show enhanced in vitro expression of a number of virulence-associated genes and of strains that do not express pertactin, an important aP component. Clearly, the identification of more effective B. pertussis vaccine antigens is of utmost importance. To identify novel antigens, we used proteomics to identify B. pertussis proteins regulated by the master virulence regulatory system BvgAS in vitro. Five candidates proteins were selected and it was confirmed that they were also expressed in the lungs of naïve mice seven days after infection. The five proteins were expressed in recombinant form, adjuvanted with alum and used to immunize mice as stand-alone antigens. Subsequent respiratory challenge showed that immunization with the autotransporters Vag8 and SphB1 significantly reduced bacterial load in the lungs. Whilst these antigens induced strong opsonizing antibody responses, we found that none of the tested alum-adjuvanted vaccines - including a three-component aP - reduced bacterial load in the nasopharynx, suggesting that alternative immunological responses may be required for efficient bacterial clearance from the nasopharynx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.